SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Retrophin, Inc. to Contact Brower Piven Before the December 19, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- RTRX


STEVENSON, Md., Nov. 19, 2014 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Retrophin, Inc. ("Retrophin" or the "Company") (Nasdaq:RTRX) securities during the period between March 27, 2014 and September 30, 2014, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until December 19, 2014 to seek appointment as lead plaintiff.

If you have suffered a loss from investment in Retrophin securities purchased on or after March 27, 2014 and held through the revelation of negative information during and/or at the end of the Class Period, as described below, and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Company units during the Class Period. Brower Piven also encourages anyone with information regarding the Company's conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period stock grants to employees and that Retrophin's founder and Chief Executive Officer was trading Company stock in violation of the Company's Incentive Compensation Plan and other securities rules and that these trading irregularities included grants of shares in violation of the Company's Incentive Compensation Plan. According to the complaint, following the Company's September 16, 2014 announcement that on September 15, 2014, it had reached an agreement with its Chief Financial Officer, Marc Panoff, pursuant to which Mr. Panoff's employment with the Company will terminate, effective as of February 28, 2015 and that on September 10, 2014, Jeffrey Paley, MD abruptly stepped down as a member of the Board of Directors and the Company's September 30, 2014 announcement its Board of Directors terminated its Chief Executive Officer, Martin Shkreli, effective immediately, the value of Retrophin shares declined significantly.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.



            

Contact Data